High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma

被引:42
作者
Owens, TS [1 ]
Dodds, H [1 ]
Fricke, K [1 ]
Hanna, SK [1 ]
Crews, KR [1 ]
机构
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 788卷 / 01期
关键词
irinotecan; SN-38;
D O I
10.1016/S1570-0232(02)01016-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Irinotecan (CPT-11), a camptothecin analog, is metabolized to SN-38, an active topoisomerase I inhibitor, and inactive metabolites, including APC and SN-38 glucuronide (SN-38G). A high-performance liquid chromatographic assay method to simultaneously measure the lactone and carboxylate forms of CPT-11, SN-38, SN-38G, and APC in human plasma was developed. Chromatography was accomplished with a reversed-phase C-8 column and fluorescence detection. A gradient mobile phase system was used. The buffer for mobile phase A consisted of 0.75 M ammonium acetate, 5 mM tetrabutylammonium phosphate (pH 6.0), and acetonitrile (86:14, v/v). The buffer for mobile phase B was identical to mobile phase A with the exception of the concentration (50:50, v/v). Precipitation of plasma proteins was performed with cold methanol. The linear range of detection of the lactone and carboxylate forms of SN-38, SN-38G, and APC was 2-25 ng/ml, and 5-300 ng/ml for CPT-11. The limit of quantitation for the analytes ranged from 0.5 to 5 ng/ml. Analysis of patients' plasma samples obtained before and after CPT-11 administration showed that the assay is suitable for measuring lactone and carboxylate forms of CPT-11, SN-38, SN-38G, and APC in clinical studies. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 17 条
[1]   UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan [J].
Ando, Y ;
Saka, H ;
Asai, G ;
Sugiura, S ;
Shimokata, K ;
Kamataki, T .
ANNALS OF ONCOLOGY, 1998, 9 (08) :845-847
[2]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF THE NEW ANTITUMOR DRUG SK-AND-F 104864-A (NSC 609699) IN PLASMA [J].
BEIJNEN, JH ;
SMITH, BR ;
KEIJER, WJ ;
VANGIJN, R ;
HUININK, WWT ;
VLASVELD, LT ;
RODENHUIS, S ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) :789-794
[3]  
Chu XY, 1997, J PHARMACOL EXP THER, V281, P304
[4]  
Crews KR, 2002, CLIN CANCER RES, V8, P2202
[5]   PROGRAM PACKAGE FOR SIMULATION AND PARAMETER-ESTIMATION IN PHARMACOKINETIC SYSTEMS [J].
DARGENIO, DZ ;
SCHUMITZKY, A .
COMPUTER PROGRAMS IN BIOMEDICINE, 1979, 9 (02) :115-134
[6]   Irinotecan therapy in adults with recurrent or progressive malignant glioma [J].
Friedman, HS ;
Petros, WP ;
Friedman, AH ;
Schaaf, LJ ;
Kerby, T ;
Lawyer, J ;
Parry, M ;
Houghton, PJ ;
Lovell, S ;
Rasheed, K ;
Cloughsey, T ;
Stewart, ES ;
Colvin, OM ;
Provenzale, JM ;
McLendon, RE ;
Bigner, DD ;
Cokgor, I ;
Haglund, M ;
Rich, J ;
Ashley, D ;
Malczyn, J ;
Elfring, GL ;
Miller, LL .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1516-1525
[7]  
GOTTLIEB JA, 1972, CANCER CHEMOTH REP 1, V56, P103
[8]  
GUPTA E, 1994, CANCER RES, V54, P3723
[9]   MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY [J].
HERTZBERG, RP ;
CARANFA, MJ ;
HOLDEN, KG ;
JAKAS, DR ;
GALLAGHER, G ;
MATTERN, MR ;
MONG, SM ;
BARTUS, JO ;
JOHNSON, RK ;
KINGSBURY, WD .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) :715-720
[10]   Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism [J].
Iyer, L ;
Hall, D ;
Das, S ;
Mortell, MA ;
Ramírez, J ;
Kim, S ;
Di Rienzo, A ;
Ratain, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) :576-582